Treatment of Children With GH in the United States and Europe: Long-Term Follow-Up From NordiNet® IOS and ANSWER Program.

ABSTRACT:

Context

Understanding real-world prescribing of GH may help improve treatment of eligible patients.

Objective

Overall: to assess real-world effectiveness and safety of GH (Norditropin). This analysis: to compare clinical characteristics of GH-treated children in the United States and Europe.

Design

The American Norditropin Studies: Web-Enabled Research Program (ANSWER; 2002 to 2016, United States) and the NordiNet International Outcome Study (NordiNet IOS; 2006 to 2016, Europe) were multicenter longitudinal observational cohort studies.

Setting

Data were recorded in 207 (United States) and 469 (Europe) clinics.

Participants

Patients with GH deficiency, Turner syndrome, Noonan syndrome, idiopathic short stature, Prader-Willi syndrome, or born small for ge

SUBMITTER: Savendahl L 

PROVIDER: S-EPMC6812718 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature